A panel of vaccine advisers at the Food and Drug Administration will meet Friday to discuss whether the agency should grant emergency use authorization to the COVID-19 vaccine developed by Johnson & Johnson-owned Janssen Pharmaceuticals. Here are the answers to the most pressing questions.
How efficacious is the vaccine?
The FDA’s panel of vaccine experts reported Wednesday that the vaccine was 66% effective overall in preventing moderate and severe COVID-19 cases. The vaccine was also demonstrated to by roughly 85% effective overall at preventing hospitalization and 100% effective at preventing death in all three regions where the shot was tested.